Statement of Comprehensive Income

Comprehensive income is the change in equity (net assets) of a business enterprise during a period from transactions and other events and circumstances from non-owners sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.

Allergan PLC, consolidated statement of comprehensive income

US$ in thousands

12 months ended:	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015
Net income (loss)	(5,265,100)	(5,086,200)	(4,118,900)	14,979,500)	3,919,400)
Foreign currency translation gains (losses)	(151,800)	(474,400)	1,248,000)	(441,600)	(129,900)
Net impact of other-than-temporary loss on investment in Teva securities	—)	—)	1,599,400)	—)	—)
Impact of Teva Transaction	—)	—)	—)	1,544,800)	—)
Unrealized gains (losses), net of tax	13,800)	(38,100)	111,700)	(1,647,500)	101,200)
Other comprehensive income (loss), net of tax	(138,000)	(512,500)	2,959,100)	(544,300)	(28,700)
Comprehensive income (loss)	(5,403,100)	(5,598,700)	(1,159,800)	14,435,200)	3,890,700)
Comprehensive income attributable to noncontrolling interest	(5,900)	(10,200)	(6,600)	(6,100)	(4,200)
Comprehensive income (loss) attributable to ordinary shareholders	(5,409,000)	(5,608,900)	(1,166,400)	14,429,100)	3,886,500)

Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).

Net Income (Loss): The net income exhibited significant volatility over the period. It was positive in 2015 and 2016, with an especially high peak in 2016. Subsequently, the company reported losses for three consecutive years from 2017 to 2019, with losses deepening slightly each year.
Foreign Currency Translation Gains (Losses): Foreign currency translation effects were generally negative or minimal except in 2017 when a positive gain was noted. Both 2015 and 2016 showed moderate losses, with a return to losses in 2018 and 2019, though these were smaller in magnitude compared to the earlier years.
Net Impact of Other-Than-Temporary Loss on Investment in Teva Securities: This unique item appeared only in 2017, registering a substantial loss impact, which may have contributed to the negative net income in that year.
Impact of Teva Transaction: The impact related to the Teva transaction was recorded solely in 2016, showing a positive value that likely influenced the unusually high net income in that year.
Unrealized Gains (Losses), Net of Tax: Unrealized gains and losses fluctuated noticeably, with a loss in 2016, gains in 2015 and 2017, and relatively small fluctuations in 2018 and 2019. The pattern indicates variability in unrealized market gains or losses.
Other Comprehensive Income (Loss), Net of Tax: Other comprehensive income also showed volatility, with a notable loss in 2016, a significant gain in 2017, and losses again in the last two years. This suggests swings in components such as foreign currency items, pension adjustments, or other non-operating items.
Comprehensive Income (Loss): Comprehensive income mirrored the trends in net income, being positive in 2015 and 2016, with a peak in 2016 before turning negative in the subsequent years. The losses in later years increased in magnitude, reflecting the decline in overall financial performance.
Comprehensive Income Attributable to Noncontrolling Interest: The share of comprehensive income attributable to noncontrolling interests remained fairly small and negative throughout the period, with minor fluctuations but no clear trend.
Comprehensive Income (Loss) Attributable to Ordinary Shareholders: The comprehensive income attributable to ordinary shareholders closely tracked the overall comprehensive income, showing strong positive results in 2015 and 2016 before turning negative from 2017 onwards, indicating sustained challenges impacting shareholders' equity.

Download chart

Allergan PLC (NYSE:AGN)

Statement of Comprehensive Income